Synergistic Antitumor Efficacy of Aspirin plus Lenvatinib in Hepatocellular Carcinoma via Regulating of Diverse Signaling Pathways

Investigators evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, they demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy.